PCRX News and Press, Pacira BioSciences Inc. From 01/07/23

Summary Reluctancy of management to provide forward estimates points to challenges in end-markets, and a key risk by estimation. Sequential sales growth looks to have stalled based on the monthly earnings releases, but we'll have to wait and see. Investor reaction to commentary on p...

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 millio...

TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM EST) on Monday, January 9, 2023. Live audio of the event can be accessed by visiting the ...

Health solutions company Pacira BioSciences ( NASDAQ: PCRX ) said its November preliminary unaudited net product sales stood at $57.5M. The company's net product sales include the products Exparel, Zilretta and the iovera system. Exparel net product sales were $46M, compared with ...

TAMPA, Fla., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of November 2022. Th...

New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients PR Newswire Nearly 60% of patients live in pain for 5+ years and 30% for 10 years or longer TAMPA, Fla. , Nov. 17, 2022 /PRNews...

Pacira BioSciences ( NASDAQ: PCRX ) has reported prelim net product sales of $54.9M for October 2022. EXPAREL net product sales were $45M, compared with $42.5M for October 2021, with average daily sales up 106% Y/Y. ZILRETTA net product sales were $8.6M, while iovera n...

-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today repo...

TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 15 th at 8...

Pacira BioSciences ( NASDAQ: PCRX ) posted wider-than-expected quarterly loss, as costs increased. Revenue rose 31.1% Y/Y to $167.5M in-line with estimates. Q3 GAAP EPS of -$0.02 misses by $0.39. Non-GAAP net income was $29.9 million, or $0.64 per share in the thir...